Morgan Stanley analyst Maxwell Skor assumed coverage of TScan Therapeutics (TCRX) with an Overweight rating and $10 price target Recent Phase 1 ALLOHA data showed product candidates TSC-100 and TSC-101 outperformed the control arm with 8% of patients relapsing versus 33% in the control arm, notes the analyst, who is focused on additional data from the ALLOHA trial expected by year-end and safety/response data from the multiplex solid tumor program in the second half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCRX:
- TScan Therapeutics: Promising Advances in TCR-Engineered Cancer Therapies Justify Buy Rating
- Positive Buy Rating for TScan Therapeutics Driven by Promising Clinical Data and Strong Financial Position
- TScan Therapeutics price target lowered to $3 from $14 at Barclays
- Positive Outlook for TScan Therapeutics: Buy Rating Affirmed Due to Promising TCR-T Cell Therapy Progress and Solid Financial Position
- Promising Clinical Differentiation and Strategic Advancements Drive Buy Rating for TScan Therapeutics